Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a research note issued to investors on Saturday.

ATRA has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. Canaccord Genuity Group set a $13.00 target price on shares of Atara Biotherapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.50.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $9.58 on Friday. The firm’s 50-day moving average is $5.75 and its 200-day moving average is $9.12. The stock has a market cap of $86.32 million, a price-to-earnings ratio of -14.30 and a beta of -0.30. Atara Biotherapeutics has a 52-week low of $3.92 and a 52-week high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $2.90 million. Atara Biotherapeutics had a negative net margin of 40.91% and a negative return on equity of 79.12%. Sell-side analysts predict that Atara Biotherapeutics will post 0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea sold 313,446 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $10.10, for a total value of $3,165,804.60. Following the transaction, the insider directly owned 1,011,000 shares of the company’s stock, valued at $10,211,100. This represents a 23.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 41.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in Atara Biotherapeutics in the 2nd quarter valued at about $31,000. Dimensional Fund Advisors LP bought a new position in Atara Biotherapeutics in the 4th quarter valued at about $181,000. Walleye Capital LLC bought a new position in Atara Biotherapeutics in the 4th quarter valued at about $220,000. Marshall Wace LLP bought a new position in Atara Biotherapeutics in the 2nd quarter valued at about $327,000. Finally, Quadrature Capital Ltd raised its holdings in Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 3,779 shares during the period. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics News Summary

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: An analyst raised Atara Biotherapeutics’ price target by 25% to $11.90, which can signal improved expectations for the stock’s outlook. Atara Biotherapeutics (ATRA) price target increased by 25.00% to 11.90
• Neutral Sentiment: Multiple law firms announced or reiterated class action lawsuits and lead-plaintiff deadlines for investors who bought ATRA shares between May 20, 2024 and January 9, 2026. These updates keep the legal situation in focus, but they do not by themselves resolve the case or quantify the financial impact. Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
• Neutral Sentiment: Additional firms, including Rosen and Faruqi & Faruqi, reminded investors about the May 22 lead-plaintiff deadline, reinforcing that litigation risk remains an overhang. ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATRA
• Negative Sentiment: A new securities class action has been filed against Atara Biotherapeutics and certain officers, alleging violations of federal securities laws and seeking damages on behalf of investors. This can pressure the stock by increasing legal uncertainty and potential settlement costs. Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
• Negative Sentiment: TipRanks highlighted manufacturing and supply-chain risks threatening Atara’s cell therapy pipeline, adding to concerns around execution and commercialization. Manufacturing and Supply-Chain Risks Threaten Atara Biotherapeutics’ Cell Therapy Pipeline

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.